

# Pelvic and muscular metastasis of a renal cell carcinoma: A case report

CAROLINA D'ELIA<sup>1</sup>, TOMMASO CAI<sup>1</sup>, LORENZO LUCIANI<sup>1</sup>,  
MARIELLA BONZANINI<sup>2</sup> and GIANNI MALOSSINI<sup>1</sup>

Departments of <sup>1</sup>Urology and <sup>2</sup>Pathology and Diagnostic, Santa Chiara Hospital, Trento I-938100, Italy

Received October 12, 2012; Accepted January 4, 2013

DOI: 10.3892/ol.2013.1172

**Abstract.** We report a case of an uncommon site of metastasis of a renal cell carcinoma. The most common sites of renal cell carcinoma metastasis are the lung, lymph nodes, liver, bone and adrenal glands; skeletal muscle metastasis is a rare occurrence. We report the case of a 75-year-old female who underwent a laparoscopic left radical nephrectomy for a renal neoplasm in 2011. The histological examination revealed the presence of a renal cell carcinoma, Fuhrman grade 2, with extensive necrosis and phlogosis areas (TNM 2009 RCC pT2a). Ten months later, the patient noted an indolent swelling on the proximal third of the right thigh and underwent an ultrasonographic and CT evaluation, documenting the presence of a pathological, solid bulk in the front of the right iliac vessels and in the rectus femoris muscle. The fine needle biopsy revealed a metastasis of renal cell carcinoma. The patient underwent 4 cycles of sunitinib therapy, followed by 3 cycles of salvage therapy with sorafenib, which were well tolerated. This unpredictable behaviour of RCC suggests the need to perform a thorough follow-up of patients.

## Introduction

We report a case of a very unusual site of metastasis of a renal cell carcinoma. Renal cell carcinoma represents 2-3% of all malignancies (1), with an annual increase in incidence of ~2%. Renal cell carcinoma represents ~90% of kidney neoplasms (2); 20-25% of the patients initially present with advanced disease and ~5% present with a single metastatic site (3).

Patients affected by renal cell carcinoma will develop metastasis during the follow-up period in ~30% of cases (4). The most common sites of renal cell carcinoma metastases are the lung (50%), lymph nodes (35%), liver (30%), bone (30%)

and adrenal glands (5%) (5); skeletal muscle metastasis is a rare occurrence.

## Case report

A 76-year-old Caucasian female who was a non-smoker, with a history of heart ischemic disease, hypertension, anemia and diabetes, underwent a laparoscopic left radical nephrectomy for a renal neoplasm of 10x7 cm in the superior left renal pole in 2011. The postoperative course was uneventful and the patient was discharged after 6 days. The histological examination revealed the presence of a renal cell carcinoma, Fuhrman grade 2, with extensive necrosis and phlogosis areas (TNM 2009 RCC pT2a). Informed consent was obtained from the patient.

After discharge, the patient was readmitted for a sciatica episode and underwent two abdomen ultrasonography examinations, with no notable pathological findings.

After a few days, the patient noted an indolent swelling in the proximal third of the right thigh. The patient subsequently underwent ultrasonographic evaluation, revealing the presence of a solid, vascularized mass that was ~40x22 mm in size.

The subsequent CT documented the presence of a pathological, solid, dishomogeneous bulk that was ~4.5 cm diameter, in the front of the right iliac vessels, immediately cranial to the inguinal region. Another smaller (1.5 cm) lesion was observed in the ipsilateral inguinal region, while an additional solid expansive lesion was noted in the *rectus femoris* muscle (Fig. 1).

The fine needle biopsy of the muscle mass documented a metastasis of renal cell carcinoma (Fig. 2). The histochemical analysis revealed positive staining for vimentin and CAM, and negative staining for cytokeratin 7.

Moreover, we performed a cerebral CT and a total body bone scan, in order to achieve a complete stadiation of the patient. Neither of the examinations revealed further metastatic localization.

A joint evaluation of the patient was performed with the oncologist, the general surgeon and the radiotherapist. With regard to the pathological stage of the disease and the comorbidity of the patient, it was decided to refer the patient for targeted therapy with sunitinib.

Therefore, the patient underwent 2 cycles of sunitinib therapy. Subsequently, due to the onset of edema in the right lower limb, the patient underwent an abdominal CT, revealing

---

*Correspondence to:* Dr Carolina D'Elia, Department of Urology, Santa Chiara Hospital, 9 Largo Medaglie d'Oro, Trento I-938100, Italy  
E-mail: karolinedelia@gmail.com

**Key words:** renal cell carcinoma, metastasis, muscular, pelvic




Figure 1. CT scan showing a solid expansive lesion in the rectus femoris muscle.




Figure 2. (A) Histochemical assay of fine needle biopsy of the mass (Papanicolaou; magnification, x200). (B) Histochemical assay of fine needle biopsy of the mass is positive for vimentin and CAM and (D) negative for cytokeratin 7 (magnification, x400).

a nodal progression of the disease along the right femoral and iliac vessels. The patient underwent 6 further cycles of salvage therapy with sorafenib, which were well tolerated. The subsequent CT scan revealed a lymphonodal progression of disease.

## Discussion

Renal cell carcinoma presents a unpredictable behavior, even after surgical therapy, and the median time to recurrence may be extensive. McNichols *et al* demonstrated that 11% of metastatic RCC cases occurred more than 10 years after the initial diagnosis, even after complete resection (6).

Skeletal muscle metastasis is rare, regardless of the site of origin. A limited number of cases concerning skeletal muscle metastasis have been described in the literature, and its prevalence is ~1.6% (7). Possibly the first case of skeletal metastasis originating from an RCC was reported in 1979 by Chandler *et al*, describing a slowly enlarging biceps muscle mass as an atypical presentation of RCC, diagnosed with a soft tissue biopsy needle (8). More recently, Ali *et al* reported the occurrence of a persistent left arm swelling accompanied by wrist drop as an atypical presentation of renal cell carcinoma (9).

Several other studies have demonstrated the development of muscular metastasis during the follow-up period after radical nephrectomy, with onset times varying between a number of months and 19 years. Additionally, muscular metastasis has been found in various muscular localizations, such as, respectively, the thigh (at the level of the great adductor muscle or, in our case, the *rectus femoris*), the iliopsoas muscle or the erector spine muscle (10-12).

The mechanism involved in the metastatic spreading to the skeletal muscular tissue is not fully understood. Several explanations have been suggested, such as direct invasion or hematogenous spreading. Moreover, Merimsky *et al* suggested that the relative resistance of the muscular tissue to the metastatic spreading should be investigated further (13).

The surgical resection of a solitary RCC metastasis improves the survival of patients with metastatic RCC. In the present case, with regard to the presence of multiple metastases and the comorbidity, and in accordance with the wishes of the patient, we decided to refrain from administering surgical treatment and the patient was referred to the oncologist.

At present, there is no agreement with regard to a surveillance protocol for patients treated for RCC. Additionally, it is unclear whether an early recurrence diagnosis will improve the survival of the patients (14). However, an early recognition of tumor recurrences means that the therapeutic approach to the disease, whether it be surgical metastasectomy or systemic treatment, through the use of targeted therapies, will be more effective.

The unpredictable behaviour of RCC suggests the need to perform a thorough follow-up of patients, and to investigate all soft tissue masses, including cytopathologically, that develop in patients with a history of RCC.

## References

1. European Network of Cancer Registries. Eurocim version 4.0. European incidence database V2.3, 730 entity dictionary (2001), Lyon, 2001.

2. Kovacs G, Akhtar M, Beckwith BJ, Bugert P, Cooper CS, Delahunt B, Eble JN, Fleming S, Ljungberg B, Medeiros LJ, *et al*: The Heidelberg classification of renal cell tumours. *J Pathol* 183: 131-133, 1997.
3. Gupta K, Miller JD, Li JZ, Russell MW and Charbonneau C: Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. *Cancer Treat Rev* 34: 193-205, 2008.
4. Flaminian RC, Campbell SC, Clark JI and Picken MM: Metastatic renal cell carcinoma. *Curr Treat Options Oncol* 4: 385-390, 2003.
5. Hanno P, Wein A and Malkowicz SB (eds): *Clinical Manual of Urology*. 3rd edition. McGraw Hill, New York, NY, pp498, 2001.
6. McNichols DW, Segura JW and DeWeerd JH: Renal cell carcinoma: long term survival and late recurrence. *J Urol* 126: 17-23, 1981.
7. Vidart A, Fehri K and Pfister C: Unusual metastasis of renal carcinoma. *Ann Urol (Paris)* 40: 211-219, 2006 (In French).
8. Chandler RW, Shulman I and Moore TM: Renal cell carcinoma presenting as a skeletal muscle mass: a case report. *Clin Orthop Relat Res* 145: 227-229, 1979.
9. Ali SH, Chugtai H, Alali F, Fiaczok B and Verardi M: Wrist drop: an atypical presentation of renal cell carcinoma. *Am J Med Sci* 342: 170-173, 2011.
10. Picchio M, Mascetti C, Tanga I and Spaziani E: Metastasis from renal cell carcinoma presenting as skeletal muscle mass: a case report. *Acta Chir Belg* 110: 399-401, 2010.
11. Taira H, Ishii T, Inoue Y and Hiratsuka Y: Solitary psoas muscle metastasis after radical nephrectomy for renal cell carcinoma. *Int J Urol* 12: 96-97, 2005.
12. Hur J, Yoon CS and Jung WH: Multiple skeletal metastases from renal cell carcinoma 19 years after radical nephrectomy. *Acta Radiol* 48: 238-241, 2007.
13. Merimsky O, Levine T and Chiatchik S: Recurrent solitary metastasis of renal cell carcinoma in skeletal muscle. *Tumori* 67: 407-409, 1990.
14. Ljungberg B, Cowan NC, Hanbury DC, Hora M, Kuczyk MA, Merseburger AS, Patard JJ, Mulders PF, Sinescu IC; European Association of Urology Guideline Group: EAU guidelines on renal cell carcinoma: the 2010 update. *Eur Urol* 58: 398-406, 2010.